2023 Winners

Menlo Micro is on a mission to create a more energy efficient and sustainable world, with an entirely new category of electronic switches. The Ideal Switch® eliminates compromises and tradeoffs by combining the benefits of electromechanical and solid-state switches into the best of both worlds.

Sientra is a diversified surgical aesthetics company serving the needs of board-certified plastic surgeons for augmentation and reconstruction, providing the safest and most innovative solutions for the best aesthetic outcomes.

Enevate develops and licenses battery technology for electric vehicles (EVs), with a vision of EVs charging as fast as refueling gas cars, and accelerating EVs’ mass adoption. Enevate’s silicon-dominant anodes and cells achieve five-minute fast charging with high energy density, low-temperature operation, low cost and safety advantages over conventional batteries.

Matregenix is a global leader in nanofiber technology, offering highly customizable nanofibrous materials for a diverse range of applications. We are constantly pushing the boundaries of nanofiber technology with our cutting-edge platforms, focusing specifically on filtration and biomedical fields. Our state-of-the-art electrospinning machines and comprehensive contract development and manufacturing services make us a one-stop-shop for nanofiber solutions, helping manufacturers bring their innovations to market.

Cloudvirga is a financial technology company that empowers mortgage lenders with innovative tools through its Horizon SaaS platform, streamlining processes, reducing costs, and enabling exceptional service to their borrowers. Cloudvirga provides a comprehensive suite of software solutions for retail and wholesale lenders. 

Sapphire Technologies develops and manufactures energy recovery systems such as turboexpanders that harness the power of gas expansion to produce reliable and clean electricity – reducing global carbon footprint. Our systems are designed to convert energy wasted in pressure reduction processes into electric power. By recovering this wasted pressure energy, we help companies reduce carbon emissions and generate cashflow.

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products designed to treat a wide spectrum of vascular disease from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix’s current commercial EVAR (Endovascular Aneurysm Repair) products include AFX®2 and the ALTO® Abdominal Stent Graft System.  Most recently, the DETOUR System was approved by the FDA and expands the company’s therapeutic offerings to PAD (peripheral artery disease).

CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence (AI) and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visitwww.cath.works and follow @CathWorks on Twitter and LinkedIn.

Maáza Martin has over 16 years of experience in healthcare, with nearly 10 years in the eye care industry, leading cross-functional teams to identify market opportunities and deliver creative, effective solutions to drive business objectives. Currently Maáza serves as Senior Director, Marketing at Tarsus Pharmaceuticals, where she is responsible for developing and leading the healthcare professional marketing strategy for the launch of the company’s investigational therapy for Demodex blepharitis, XDEMVY™ (lotilaner ophthalmic solution) 0.25%, which is the first FDA-approved treatment for this highly prevalent eye disease.